![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LM Winn and PG Wells
Faculty of Pharmacy, University of Toronto, Ontario, Canada.
A murine embryo culture model was used to investigate phenytoin- initiated embryonic DNA oxidation and dysmorphogenesis and to determine the embryoprotective potential of superoxide dismutase and catalase, which detoxify reactive oxygen species. Gestational day 9.5 CD-1 embryos were cultured for up to 24 hr at 37 degrees in medium containing phenytoin (20 micrograms/ml, 80 microM) or its vehicle (0.002 N NaOH). Embryos cultured for 24 hr were examined for embryotoxicity. After varying durations of incubation, embryonic DNA was isolated and purified, and DNA oxidation was determined from the formation of 8-hydroxy-2'-deoxyguanosine (8-OH-2'-dG). Control embryos showed an early increase in 8-OH-2'-dG levels that was maximal between 2 and 4 hr, followed by a small but significant decrease over 24 hr, with no evidence of embryopathy. Phenytoin-treated embryos within 4 hr also demonstrated maximal 8-OH-2'-dG formation, which was substantially greater than that of controls, with a maximal 3-fold increase over controls at 24 hr (p < 0.05). In wash-out studies, embryos removed from the phenytoin-containing medium after 4 hr and then cultured in phenytoin-free medium for an additional 20-hr period showed no decrease in either 8-OH-2'-dG levels or embryotoxicity, compared with embryos incubated in the presence of phenytoin for 24 hr. Embryos exposed to phenytoin demonstrated substantial dysmorphogenesis, as evidenced by decreases in anterior neuropore closure, turning, yolk sac diameter, crown-rump length, and somite development (p < 0.05). Superoxide dismutase and catalase virtually eliminated phenytoin-initiated 8-OH-2'- dG formation and reduced or completely eliminated all phenytoin- initiated dysmorphological anomalies (p < 0.05). These results suggest that embryonic DNA oxidation constitutes teratologically important molecular target damage, and they provide the first direct evidence that free radical-mediated oxidative stress plays a critical role in phenytoin teratogenesis.
This article has been cited by other articles:
|
|
 |
|
  Y. Bhuller, W. Jeng, and P. G. Wells Variable In Vivo Embryoprotective Role for Ataxia-Telangiectasia-Mutated against Constitutive and Phenytoin-Enhanced Oxidative Stress in Atm Knockout Mice Toxicol. Sci., September 1, 2006; 93(1): 146 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bhuller and P. G. Wells A Developmental Role for Ataxia-Telangiectasia Mutated in Protecting the Embryo from Spontaneous and Phenytoin-Enhanced Embryopathies in Culture Toxicol. Sci., September 1, 2006; 93(1): 156 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Chen and P. G. Wells Enhanced tumorigenesis in p53 knockout mice exposed in utero to high-dose vitamin E Carcinogenesis, July 1, 2006; 27(7): 1358 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. N. Defoort, P. M. Kim, and L. M. Winn Valproic Acid Increases Conservative Homologous Recombination Frequency and Reactive Oxygen Species Formation: A Potential Mechanism for Valproic Acid-Induced Neural Tube Defects Mol. Pharmacol., April 1, 2006; 69(4): 1304 - 1310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Kennedy, S. Memet, and P. G. Wells Antisense Evidence for Nuclear Factor-{kappa}B-Dependent Embryopathies Initiated by Phenytoin-Enhanced Oxidative Stress Mol. Pharmacol., September 1, 2004; 66(3): 404 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Winn, P. M. Kim, and J. A. Nickoloff Oxidative Stress-Induced Homologous Recombination As a Novel Mechanism for Phenytoin-Initiated Toxicity J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 523 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Pagano Redox-modulated xenobiotic action and ROS formation: a mirror or a window? Human and Experimental Toxicology, February 1, 2002; 21(2): 77 - 81. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Pendeville, N. Carpino, J.-C. Marine, Y. Takahashi, M. Muller, J. A. Martial, and J. L. Cleveland The Ornithine Decarboxylase Gene Is Essential for Cell Survival during Early Murine Development Mol. Cell. Biol., October 1, 2001; 21(19): 6549 - 6558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gallagher and K. M. Sheehy Effects of Phenytoin on Glutathione Status and Oxidative Stress Biomarker Gene mRNA Levels in Cultured Precision Human Liver Slices Toxicol. Sci., January 1, 2001; 59(1): 118 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. NICOL, J. ZIELENSKI, L.-C. TSUI, and P. G. WELLS An embryoprotective role for glucose-6-phosphate dehydrogenase in developmental oxidative stress and chemical teratogenesis FASEB J, January 1, 2000; 14(1): 111 - 127. [Abstract] [Full Text]
|
|
|
|
|
|
B. F. Hales Post-Translational Regulation of AP-1 Transcription Factor DNA-Binding Activity in the Rat Conceptus Mol. Pharmacol., September 1, 1999; 56(3): 537 - 544. [Abstract] [Full Text]
|
|
|
|
|
|
R. C.-T. Yu, T.-C. Lee, T.C. Wang, and J.-H. Li Genetic toxicity of cocaine Carcinogenesis, July 1, 1999; 20(7): 1193 - 1199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Winn, P. M. Kim, and P. G. Wells Investigation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone for In Vivo and In Vitro Murine Embryopathy and Embryonic ras Mutations J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1128 - 1135. [Abstract] [Full Text]
|
|
|
|
|
|
B. F. Hales Oxidative Stress Regulates the Expression and Activity of Transcription Factor Activator Protein-1 in Rat Conceptus J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1085 - 1093. [Abstract] [Full Text]
|
|
|
|
|
|
P. M. Kim, L. M. Winn, T. Parman, and P. G. Wells UDP-Glucuronosyltransferase-mediated Protection Against In Vitro DNA Oxidation and Micronucleus Formation Initiated by Phenytoin and Its Embryotoxic Metabolite 5-(p-Hydroxyphenyl)-5-phenylhydantoin J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 200 - 209. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
